Scholarlink

<p>The treatment of complex inflammatory diseases like dry eye disease (DED) is hampered by the intertwined pathologies of inflammation and oxidative stress, which form a self-amplifying vicious cycle. Here, we report an&#xa0;intelligent nanoplatform (CFMPDA)&#xa0;designed to actively navigate and disrupt this cycle through&#xa0;sequential, pathology-responsive targeting. CFMPDA is constructed by encapsulating the anti-inflammatory agent Fuziline within a&#xa0;mesoporous polydopamine (MPDA) nanoscavenger&#xa0;and conjugating&#xa0;CCL2-targeting antibodies&#xa0;on its surface. This design enables a two-stage therapeutic strategy: first,&#xa0;CCL2-mediated anchoring&#xa0;to the inflamed cornea, providing&#xa0;disease severity-dependent retention&#xa0;that overcomes rapid ocular clearance; second, subsequent&#xa0;mitochondrial targeting&#xa0;to deliver combined anti-inflammatory and antioxidant therapy directly to the organelle generating pathogenic ROS. In vivo, CFMPDA demonstrated potent, synergistic efficacy in a DED mouse model, simultaneously suppressing the inflammatory cascade (IL-1β, IL-6, TNF-α, MMP9, T cell infiltration) and quenching oxidative stress, leading to comprehensive tissue repair and functional recovery that surpassed the clinical standard-Fluorometholone. This work establishes a&#xa0;versatile nanotechnology blueprint—responsive bio-interfacing coupled with programmed subcellular delivery-for the synergistic treatment of inflammatory disorders characterized by chemokine upregulation and mitochondrial dysfunction.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A sequentially targeted and pathology-responsive nanoplatform for synergistic treatment of dry eye disease via concurrent anti-inflammation and mitochondrial ROS scavenging

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月22日

查看全文
  • Liandi Huang,
  • Xin Liu,
  • Ying Yuan,
  • Bilian Ke

摘要

The treatment of complex inflammatory diseases like dry eye disease (DED) is hampered by the intertwined pathologies of inflammation and oxidative stress, which form a self-amplifying vicious cycle. Here, we report an intelligent nanoplatform (CFMPDA) designed to actively navigate and disrupt this cycle through sequential, pathology-responsive targeting. CFMPDA is constructed by encapsulating the anti-inflammatory agent Fuziline within a mesoporous polydopamine (MPDA) nanoscavenger and conjugating CCL2-targeting antibodies on its surface. This design enables a two-stage therapeutic strategy: first, CCL2-mediated anchoring to the inflamed cornea, providing disease severity-dependent retention that overcomes rapid ocular clearance; second, subsequent mitochondrial targeting to deliver combined anti-inflammatory and antioxidant therapy directly to the organelle generating pathogenic ROS. In vivo, CFMPDA demonstrated potent, synergistic efficacy in a DED mouse model, simultaneously suppressing the inflammatory cascade (IL-1β, IL-6, TNF-α, MMP9, T cell infiltration) and quenching oxidative stress, leading to comprehensive tissue repair and functional recovery that surpassed the clinical standard-Fluorometholone. This work establishes a versatile nanotechnology blueprint—responsive bio-interfacing coupled with programmed subcellular delivery-for the synergistic treatment of inflammatory disorders characterized by chemokine upregulation and mitochondrial dysfunction.

Graphical Abstract